Total Payments
$68,471
2024 Payments
$966.22
Companies
6
Transactions
84
Medicare Patients
282
Medicare Billing
$24,411
Payment Breakdown by Category
Other$46,160 (67.4%)
Consulting$14,096 (20.6%)
Food & Beverage$3,940 (5.8%)
Research$3,421 (5.0%)
Travel$853.57 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,160 | 33 | 67.4% |
| Consulting Fee | $14,096 | 3 | 20.6% |
| Food and Beverage | $3,940 | 26 | 5.8% |
| Unspecified | $3,421 | 19 | 5.0% |
| Travel and Lodging | $853.57 | 3 | 1.2% |
Payments by Type
General
$65,050
65 transactions
Research
$3,421
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| IRONSHORE PHARMACEUTICALS INC. | $48,514 | 52 | $0 (2024) |
| Adlon Therapeutics L.P. | $9,296 | 2 | $0 (2022) |
| Supernus Pharmaceuticals, Inc. | $5,740 | 10 | $0 (2024) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $2,378 | 13 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $1,500 | 1 | $0 (2018) |
| Neos Therapeutics, LP | $1,044 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $966.22 | 3 | Supernus Pharmaceuticals, Inc. ($878.29) |
| 2023 | $22.50 | 1 | Supernus Pharmaceuticals, Inc. ($22.50) |
| 2022 | $3,296 | 1 | Adlon Therapeutics L.P. ($3,296) |
| 2021 | $7,920 | 2 | Adlon Therapeutics L.P. ($6,000) |
| 2020 | $12,600 | 11 | Ironshore Pharmaceuticals Inc. ($12,600) |
| 2019 | $37,327 | 58 | Ironshore Pharmaceuticals Inc. ($33,906) |
| 2018 | $6,339 | 8 | Supernus Pharmaceuticals, Inc. ($4,839) |
All Payment Transactions
84 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $33.36 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 01/20/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | In-kind items and services | $87.93 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 01/18/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $844.93 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 01/14/2023 | Supernus Pharmaceuticals, Inc. | QELBREE (Drug) | Food and Beverage | Cash or cash equivalent | $22.50 | General |
| Category: PSYCHOLOGY | ||||||
| 06/06/2022 | Adlon Therapeutics L.P. | ADHANSIA XR (Drug) | Consulting Fee | Cash or cash equivalent | $3,296.00 | General |
| Category: PRESCRIPTION STIMULANT | ||||||
| 06/15/2021 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,920.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 03/31/2021 | Adlon Therapeutics L.P. | ADHANSIA XR (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: PRESCRIPTION STIMULANT | ||||||
| 09/15/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 09/15/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 08/12/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 06/25/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 03/18/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 03/06/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 01/30/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 01/30/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 01/24/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 01/16/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 01/14/2020 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Central Nervous Stimulant ADHD | ||||||
| 12/18/2019 | Ironshore Pharmaceuticals Inc. | Jornay PM 20mg capsules (Bottle of 100) (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Central nervous system (CNS) stimulant | ||||||
| 12/10/2019 | Ironshore Pharmaceuticals Inc. | Jornay PM 20mg capsules (Bottle of 100) (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Central nervous system (CNS) stimulant | ||||||
| 11/22/2019 | Ironshore Pharmaceuticals Inc. | Jornay PM 20mg capsules (Bottle of 100) (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Central nervous system (CNS) stimulant | ||||||
| 11/14/2019 | Ironshore Pharmaceuticals Inc. | Jornay PM 20mg capsules (Bottle of 100) (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Central nervous system (CNS) stimulant | ||||||
| 11/14/2019 | Ironshore Pharmaceuticals Inc. | Jornay PM 20mg capsules (Bottle of 100) (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: Central nervous system (CNS) stimulant | ||||||
| 11/12/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $247.47 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER • Category: PSYCHIATRY | ||||||
| 11/12/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $182.93 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER • Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,418 | 7 |
| An Open-Label, Single-Dose Pharmacokinetic Study of ADZENYS XR ODT in Male and Female Children 4 to Less Than 6 Years of Age With Attention-Deficit/Hyperactivity Disorder (ADHD) | Neos Therapeutics, LP | $1,044 | 6 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $959.95 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 106 | 171 | $30,156 | $7,881 |
| 2022 | 1 | 45 | 162 | $23,652 | $5,896 |
| 2021 | 2 | 49 | 131 | $20,343 | $5,415 |
| 2020 | 3 | 82 | 136 | $20,692 | $5,218 |
Total Patients
282
Total Services
600
Medicare Billing
$24,411
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99348 | Residence visit for established patient with low level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 40 | 62 | $11,549 | $3,502 | 30.3% |
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 22 | 27 | $8,397 | $2,695 | 32.1% |
| 99347 | Residence visit for established patient with straightforward medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 44 | 82 | $10,210 | $1,684 | 16.5% |
| 99334 | Established patient custodial care facility, group care, or assisted living visit, typically 15 minutes | Office | 2022 | 45 | 162 | $23,652 | $5,896 | 24.9% |
| 99334 | Established patient assisted living visit, typically 15 minutes | Office | 2021 | 36 | 118 | $17,318 | $4,635 | 26.8% |
| 99335 | Established patient assisted living visit, typically 25 minutes | Office | 2021 | 13 | 13 | $3,025 | $780.23 | 25.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 32 | 67 | $12,174 | $2,895 | 23.8% |
| 99334 | Established patient assisted living visit, typically 15 minutes | Office | 2020 | 25 | 25 | $3,725 | $1,177 | 31.6% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 25 | 44 | $4,793 | $1,146 | 23.9% |
About Dr. Steven Pliszka, M.D
Dr. Steven Pliszka, M.D is a Child & Adolescent Psychiatry healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245249069.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Pliszka, M.D has received a total of $68,471 in payments from pharmaceutical and medical device companies, with $966.22 received in 2024. These payments were reported across 84 transactions from 6 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($46,160).
As a Medicare-enrolled provider, Pliszka has provided services to 282 Medicare beneficiaries, totaling 600 services with total Medicare billing of $24,411. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Location San Antonio, TX
- Active Since 08/08/2006
- Last Updated 05/06/2009
- Taxonomy Code 2084P0804X
- Entity Type Individual
- NPI Number 1245249069
Products in Payments
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $33,906
- JORNAY PM (Drug) $14,608
- ADHANSIA XR (Drug) $9,296
- REXULTI (Drug) $1,418
- Adzenys XR-ODT (Drug) $1,044
- Qelbree (Drug) $878.29
- QELBREE (Drug) $22.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in San Antonio
Dr. Edmund Williams, Md, MD
Child & Adolescent Psychiatry — Payments: $275,207
Child & Adolescent Psychiatry $275,207
Mary Garcia-Holguin, Md, MD
Child & Adolescent Psychiatry — Payments: $24,423
Child & Adolescent Psychiatry $24,423
Dr. Michelle Cantu, M.d, M.D
Child & Adolescent Psychiatry — Payments: $15,773
Child & Adolescent Psychiatry $15,773
Dr. Maria Dominguez, Md, MD
Child & Adolescent Psychiatry — Payments: $7,560
Child & Adolescent Psychiatry $7,560
Dr. Andrew Martin, M.d, M.D
Child & Adolescent Psychiatry — Payments: $6,098
Child & Adolescent Psychiatry $6,098
Thomas Demoor, M.d, M.D
Child & Adolescent Psychiatry — Payments: $4,568
Child & Adolescent Psychiatry $4,568